Abcellera Biologics (NASDAQ:ABCL) is a biotech firm focused on discovering and developing next-generation antibody therapies to address challenging diseases. By leveraging a proprietary technology that combines artificial intelligence, deep genomics, and a massively parallel microfluidic lab-on-a-chip platform, Abcellera aims to revolutionize the speed and efficiency of therapeutic antibody discovery. The company's projects span a range of therapeutic areas, including infectious diseases, immuno-oncology, and neurodegeneration, with the objective to rapidly transform novel molecular insights into full-spectrum antibody therapies. Abcellera’s collaborative and partnership-driven approach enables it to work alongside some of the world’s leading biopharmaceutical companies, amplifying its impact across the healthcare ecosystem.